DOCSLIB.ORG

Warfarin-Induced Skin Necrosis and Venous Limb Gangrene in the Setting of Heparin-Induced Thrombocytopenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Warfarin-Induced Skin Necrosis and Venous Limb Gangrene in the Setting of Heparin-Induced Thrombocytopenia ORIGINAL INVESTIGATION Warfarin-Induced Skin Necrosis and Venous Limb Gangrene in the Setting of Heparin-Induced Thrombocytopenia Abhay F. Srinivasan, MD; Lawrence Rice, MD; John R. Bartholomew, MD; Chandhiran Rangaswamy, MD; Lucy La Perna, DO; James E. Thompson, MD; Scott Murphy, MD; Kelty R. Baker, MD Background: Heparin-induced thrombocytopenia (HIT) emerged after 2 to 7 days, and consisted of warfarin- is a common, often catastrophic, syndrome that pro- induced skin necrosis (n=5) and venous limb gangrene duces the most hypercoagulable of states. Emerging thera- (n=2); 1 patient had both. This emerged with unop- peutic strategies use alternative anticoagulants; warfa- posed warfarin in 4 patients and as a direct thrombin in- rin’s place is being reexamined. Early in the course of hibitor was being withdrawn in 2. All had suprathera- warfarin therapy, there may be net procoagulant effects peutic international normalized ratios. One patient because of the inhibition of protein C. With HIT, it has required leg and breast amputations, and another one died. been suggested that unopposed warfarin can precipitate venous limb gangrene. There are also reports of warfarin- Conclusions: Because of the early effects on protein C, induced skin necrosis. We seek to confirm and increase warfarin can precipitate venous limb gangrene and/or skin awareness of the risks of warfarin with HIT. necrosis in the extreme hypercoagulable milieu of HIT. With HIT, unopposed warfarin should be avoided and Methods: We describe 6 patients with HIT seen at 3 caution is needed during transition from a direct throm- medical centers in whom frank or impending venous limb bin inhibitor. Warfarin should be initiated at modest doses gangrene, central skin necrosis, or both were tempo- in patients with HIT after platelet recovery. Implica- rally related to warfarin initiation. tions extend to warfarin initiation with other throm- botic diatheses. Results: At warfarin initiation, 5 patients had recog- nized HIT and 1 had it recognized later. Complications Arch Intern Med. 2004;164:66-70 ARFARIN, THE STAN- Logically, early warfarin effects on dard oral anticoagu- protein C could be deleterious in the ex- lant used by mil- treme hypercoagulable milieu surround- lions daily, may ing HIT. Unopposed warfarin continues Author affiliations are given at have procoagulant to be used pending wider appreciation of the end of the article. Drs Rice Wactions in the first days of use because the the risks. We describe 6 patients, all of and Bartholomew have been vitamin K–dependent natural anticoagu- whom met the established criteria for the consultants for and on the lant protein C has a shorter half-life than diagnosis of HIT (decrease in platelet count speakers bureau of Berlex most ␥-carboxylated procoagulants (fac- by 50% at an appropriate time after hep- Pharmaceuticals (which tors II, IX, and X). This helps explain the arin exposure without other likely causes). markets lepirudin for early emergence of warfarin-induced skin Our observations in these patients (seen heparin-induced in 3 medical centers over several years) thrombocytopenia) and necrosis, a microthrombotic lesion tropic GlaxoSmithKline (which to central fatty areas of the body. Patients confirm warfarin’s dangers and highlight markets argatroban for with congenital protein C deficiency are specific management considerations in the heparin-induced particularly susceptible.1,2 transition period from direct thrombin in- thrombocytopenia); Dr Rice has Heparin-induced thrombocytope- hibitors. received research support (not nia (HIT) is a common, often cata- for this study) from strophic, syndrome that produces the most GlaxoSmithKline; and Drs Rice hypercoagulable of states, with 30% to 75% REPORT OF CASES and Bartholomew have been of patients having thrombotic complica- consultants for The Medicines 3,4 Company (which markets tions. Warfarin therapy in patients with Summary data, including indications for bivalirudin for percutaneous HIT can cause progression of deep ve- heparin therapy, maximum recorded in- coronary intervention in nous thrombosis to venous limb gan- ternational normalized ratios (INRs), and patients with heparin-induced grene.5 Classic warfarin-induced skin ne- outcomes, for all patients are given in the thrombocytopenia). crosis has also been seen with HIT.5-10 Table. (REPRINTED) ARCH INTERN MED/ VOL 164, JAN 12, 2004 WWW.ARCHINTERNMED.COM 66 ©2004 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/24/2021 Patient Summaries Overlap of Time to Onset Warfarin Warfarin and of Complications Patient Initiation a Thrombin (While Taking Signs of Maximum No. Indication for Heparin (After HIT), d Inhibitor Warfarin), d Complications Recorded INR Outcome 1 DVT (postoperatively) −1 None 6 WISN of thigh 4.0* Sepsis and death 2 Catheter flushes and 14 4 d (lepirudin) 6 WISN of left breast 4.5 Healed and discharged from DVT the hospital while taking warfarin 3 Coronary bypass and 0 6 d (lepirudin) 7 VLG of right leg 5.8 Healed and discharged from atrial fibrillation the hospital while taking danaparoid sodium 4 Cardiac catheterization −3 None 3 WISN of breasts 3.2 Surgical debridement and pulmonary embolus 5 Pulmonary embolus −2 None 2 WISN of calves 6.1 Surgical debridement and discharged from the hospital while taking warfarin 6 Acute MI, coronary 0* None 4 WISN of breast 6.4 Mastectomy and bypass, and atrial and VLG of leg amputation fibrillation Abbreviations: DVT, deep venous thrombosis; HIT, heparin-induced thrombocytopenia; INR, international normalized ratio; MI, myocardial infarction; VLG, venous limb gangrene; WISN, warfarin-induced skin necrosis. *Estimated from available data. PATIENT 1 the arm remained pregangrenous and the platelet count remained about 100ϫ103/µL. Warfarin therapy was started at 5.0 mg/d on day 23, and increased to 7.5 A 58-year-old man had traumatic vertebral fractures re- mg/d on day 25. On day 26, lepirudin was discontinued quiring surgery. Postoperatively, he experienced fem- (INR, 3.1). A painful 10-cm black lesion with surround- oral vein thrombosis and pulmonary emboli. Intrave- ing ecchymoses appeared on the left breast on day 28. nous unfractionated heparin therapy was started, with a The INR was 4.5, and the platelet count was 87ϫ103/ platelet count of 441ϫ103/µL. Warfarin, 10 mg/d, was µL. Warfarin was discontinued, vitamin K was adminis- added on day 9. Heparin was discontinued when the plate- tered, and lepirudin therapy was resumed. The breast let count decreased to 120ϫ103/µL and to 83ϫ103/µL improved over several days, as the platelet count on days 10 and 11, respectively. Warfarin therapy was increased to 240ϫ 103/µL. Low-dose warfarin, 2.5 continued. On day 14, a necrotic ulcer appeared on the mg/d, was reinstituted and lepirudin was eventually dis- thigh (Figure, A). The prothrombin time was 21 sec- continued. Protein C and S levels were normal. onds (estimated INR, 4.0); the platelet count was 133ϫ103/µL, the fibrinogen level was normal, and fibrin- PATIENT 3 split products were mildly elevated. Warfarin was dis- continued, but the skin necrosis progressed and the pa- A 55-year-old man underwent coronary artery bypass sur- tient died of septicemia. gery and received intravenous heparin for 3 days post- operatively for atrial fibrillation. The platelet count on PATIENT 2 hospital discharge (day 7) was 224ϫ103/µL, but was 47ϫ103/µL on readmission 4 days later, with right leg After knee trauma and surgery, a 50-year-old woman deep vein thrombosis. Enzyme-linked immunosorbent had purulent material drained from her knee. Antibiot- and serotonin release assays confirmed HIT, and lepiru- ics were given via a central venous catheter flushed din therapy was initiated. Warfarin, 21 mg, was given for with unfractionated heparin. The platelet count was the next 3 days. On day 9, the INR was 2.7, the platelet 318ϫ103/µL. She was readmitted on day 8 for symp- count was 45ϫ103/µL, and lepirudin was discontinued. tomatic venographically demonstrated thromboses in The leg worsened. Lepirudin therapy was restarted with the right arm. Intravenous heparin was administered. warfarin. On day 13, the INR was 3.3 and warfarin therapy The readmission platelet count of 109ϫ 103/µL was continued alone. Thrombocytopenia persisted. On decreased the next day to 43ϫ103/µL, then to a nadir of day 14, worsening cyanosis of the leg gave the appear- 17ϫ103/µL. Heparin was discontinued, HIT was con- ance of impending venous limb gangrene. The INR was firmed by an enzyme-linked immunosorbent assay, and 5.8. Lepirudin therapy was resumed, warfarin was dis- lepirudin therapy was begun. Rapidly progressing arm continued, and vitamin K was administered. Signs of gan- cyanosis mandated alteplase for 2 days. A ventilation/ grene resolved over 2 days, as the platelet count in- perfusion scan showed a moderate probability of a pul- creased to normal. The patient was discharged to continue monary embolism. Lepirudin therapy was resumed, but taking danaparoid sodium. (REPRINTED) ARCH INTERN MED/ VOL 164, JAN 12, 2004 WWW.ARCHINTERNMED.COM 67 ©2004 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/24/2021 lepirudin was discontinued. The patient had normal pro- A tein C and S levels and negative hypercoagulability panel results. PATIENT 5 A 24-year-old woman with systemic lupus erythemato- sus received intravenous heparin for a pulmonary em- bolism. Warfarin, 10 mg/d, was added on day 3. The plate- let count decreased from 247ϫ103/µL at baseline to 83ϫ103/µL on day 5, the INR was 6.1, and painful pur- puric lesions of both calves appeared, progressing to full- thickness necrosis. HIT was diagnosed based on clinical variables and a positive enzyme-linked immunosorbent assay result. Heparin and warfarin were discontinued, as B vitamin K, fresh frozen plasma, and danaparoid were given. The patient required grafts to both legs. Recur- rent pulmonary emboli were believed to be due to cross reactivity of antibodies with danaparoid (dose, 1500 U subcutaneously twice a day; the result of serotonin re- lease for cross reactivity was positive).
Load more

Recommended publications
  • Treatment of 51 Pregnancies with Danaparoid Because of Heparin
    ©2005 Schattauer GmbH,Stuttgart Blood Coagulation, Fibrinolysis and CellularHaemostasis Treatment of 51 pregnancies withdanaparoidbecause of heparin intolerance EdelgardLindhoff-Last1 ,Hans-Joachim Kreutzenbeck2 ,Harry N. Magnani3 1 Division ofVascular Medicine,Department of Internal Medicine,University Hospital Frankfurt, Germany 2 MedicalDepartment, Celltech, Essen, Germany 3 Clinical Consultant Marketing, OrganonBV, Oss,The Netherlands Summary Pregnant patients withacute venous thrombosis or ahistoryof required (3/14) or an adverse eventled to atreatment discon- thrombosis mayneed alternative anticoagulation, when heparin tinuation (11/14).Four maternal bleeding events were recorded intolerance occurs. Onlylimited dataonthe useofthe hepari- during pregnancy, deliveryorpostpartum, twoofthemwere noiddanaparoid areavailable in literature.We reviewedthe use fatal duetoplacental problems.Three fetal deathswererec- of danaparoid in 51 pregnancies of 49 patients identified in litera- orded,all associated with maternal complications antedating da- turebetween 1981 and 2004.All patients had developed hepa- naparoiduse.Danaparoid cross-reactivity was suspectedin4 rin intolerance (32 duetoheparin-induced thrombocytopenia, HITpatientsand 5non-HITpatientswith skin reactions and was 19 mainlydue to heparin-induced skin rashes)and had acurrent confirmedserologicallyinone of the twoHIT patients tested.In and/or pasthistoryofthromboembolic complications.The initial none of fivefetal cordblood- andthree maternal breast milk- danaparoid doseregimens ranged
    [Show full text]
  • 201370Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201370Orig1s000 MEDICAL REVIEW(S) M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH Date: July 8, 2011 From: Kathy M. Robie-Suh, M.D., Ph.D. Medical Team Leader Division of Hematology Products Subject: NDA 201370, resubmission April 11, 2011 Heparin Sodium Injection (heparin sodium, USP) Sponsor: Pfizer, Inc. 235 East 42nd Street New York, NY 10017-5755 To: NDA 201370 This is the second review cycle for this 505(b)(2) application for a new Heparin Sodium Injection product derived from porcine intestine. The presentations include several containing benzyl alcohol as a preservative and one preservative-free presentation. The first cycle review of the NDA found the application acceptable from a clinical viewpoint. However, manufacturing facilities inspection identified deficiencies that precluded approval and a Complete Response (CR) letter was issued on April 7, 2011. Labeling review was not completed at that time. In the current resubmission the sponsor has responded to the identified deficiencies deleting the two heparin supplier sites where deficiencies were found. The Amended Cross-Discipline Team Leader Review by Dr. Ali Al-Hakim (6/28/2011) comments that Office of Compliance has updated its recommendation in the Establishment Evaluation System and issued “ACCEPTABLE” overall recommendation for this NDA on June 27, 2011 and therefore the NDA is recommended for approval. No new clinical information is included in the resubmission. Clinical review of the original application and the resubmission was conducted by Dr.
    [Show full text]
  • Heparin-Induced Thrombocytopenia (Hit)
    HEPARIN‐INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the diagnosis and initial management of heparin‐induced thrombocytopenia (HIT) and suspected HIT. BACKGROUND: HIT is a transient, immune‐mediated adverse drug reaction in patients recently exposed to heparin that generally produces thrombocytopenia and often results in venous and/or arterial thrombosis. HIT occurs in up to 5% of patients receiving unfractionated heparin (UFH) and in <1% who receive low molecular weight heparin (LMWH). HIT is characterised by immunoglobulin G (IgG) antibodies that recognize an antigen complex of platelet factor 4 (PF4) bound to heparin. These antibodies trigger a highly prothrombotic state by causing intravascular platelet aggregation, intense platelet, monocyte and endothelial cell activation and excessive thrombin generation. CLINICAL FEATURES: HIT typically presents with a fall in platelet count with or without venous and/or arterial thrombosis. Thrombocytopenia: A platelet count fall >30% beginning 5‐10 days after heparin exposure, in the absence of other causes of thrombocytopenia, should be considered to be HIT, unless proven otherwise. A more rapid onset of platelet count fall (often within 24 hours of heparin exposure) can occur when there is a history of heparin exposure within the preceding 3 months. Bleeding is very infrequent. Thrombosis: HIT is associated with a high risk (30‐50%) of new venous or arterial thromboembolism. Thrombosis may be the presenting clinical manifestation of HIT or can occur during or shortly after the thrombocytopenia. Other clinical manifestations of HIT: Less frequent manifestations include heparin‐induced skin lesions, adrenal hemorrhagic infarction, transient global amnesia, and acute systemic reactions (e.g. chills, dyspnea, cardiac or respiratory arrest following IV heparin bolus).
    [Show full text]
  • Low Molecular Weight Heparins and Heparinoids
    NEW DRUGS, OLD DRUGS NEW DRUGS, OLD DRUGS Low molecular weight heparins and heparinoids John W Eikelboom and Graeme J Hankey UNFRACTIONATED HEPARIN has been used in clinical ABSTRACT practice for more than 50 years and is established as an effective parenteral anticoagulant for the prevention and ■ Several low molecular weight (LMW) heparin treatment of various thrombotic disorders. However, low preparations, including dalteparin, enoxaparin and molecularThe Medical weight Journal (LMW) of heparinsAustralia haveISSN: recently 0025-729X emerged 7 October as nadroparin, as well as the heparinoid danaparoid sodium, more2002 convenient, 177 6 379-383 safe and effective alternatives to unfrac- are approved for use in Australia. 1 tionated©The heparin Medical (BoxJournal 1). of AustraliaIn Australia, 2002 wwwLMW.mja.com.au heparins are ■ LMW heparins are replacing unfractionated heparin for replacingNew Drugs,unfractionated Old Drugs heparin for preventing and treating the prevention and treatment of venous thromboembolism venous thromboembolism and for the initial treatment of and the treatment of non-ST-segment-elevation acute unstable acute coronary syndromes. The LMW heparinoid coronary syndromes. danaparoid sodium is widely used to treat immune heparin- ■ induced thrombocytopenia. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and Limitations of unfractionated heparin predictable anticoagulant response (avoiding the need
    [Show full text]
  • Anticoagulant Drugs
    Anticoagulant drugs Objectives: Introduction about coagulation cascade. Classify drugs acting as anticoagulants. Elaborate on their mechanism of action, correlating with that methods of monitoring. Contrast the limitations and benefits of injectable anticoagulants in clinical settings. Emphasis on the limitations of VKAs and on variable altering or modifying their response. Done by: Editing file Abdulaziz Alhammad, Ibrahim AlAsoos, Yousef Alsamil, Mohammed Abunayan, Sara Alkhalifah, Khalid Aburas, Atheer Alnashwan Revision: Jwaher Alharbi, Qusay Ajlan, Khalid Aburas, Atheer Alnashwan Mind Map Antiplatelet drugs Anticoagulants Fibrinolytic agents Drugs acting on Coagulation pathways Focus of the lecture Anticoagulants Parenteral Oral Anticoagulants Anticoagulants Vitamin K Direct Indirect antagonists Hirudin, Heparin and Warfarin Lepirudin Heparin related agents The most important slides are: 5, 6, 7, 8, 10 & 11 To understand better Definitions we need to understand: They prevent thrombus formation and extension by Anticoagulants inhibiting clotting factors (e.g. heparin, low molecular weight heparin, coumarins (warfarin) Antiplatelet They reduce the risk of clot formation by inhibiting drugs platelet functions (e.g. aspirin and ticlopidine). Fibrinolytic They dissolve thrombi that is already formed (e.g. agents streptokinase) Coagulation pathways: 6:27min 7:43min (thromboplastin) Endogenous inhibitors of coagulation: It’s a plasma protein that acts by inhibiting the Anti-thrombin III activated thrombin (factor IIa) and inhibits factor Xa, it is the site of action of heparin. Prostacyclin It is synthesized by endothelial cells and inhibits (prostaglandin I2) platelet aggregation. These are vitamin K dependent proteins that slow the Protein C and coagulation cascade by inactivating factor Va and VIIIa. protein S The site of action of warfarin Anticoagulants Parenteral Oral Anticoagulant Anticoagulant Act as thrombin Act as Vitamin K inhibitors either in: antagonist (e.g.
    [Show full text]
  • Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke a Randomized Controlled Trial
    Original Contributions Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke A Randomized Controlled Trial The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators Context.—Anticoagulation with unfractionated heparin is used commonly for ANTICOAGULATION with unfrac- treatment of acute ischemic stroke, but its use remains controversial because it has tionated heparin commonly is used to not been shown to be effective or safe. Low molecular weight heparins and hepa- treat persons with acute ischemic 1 rinoids have been shown to be effective in preventing deep vein thrombosis in per- stroke. However, the use of heparin re- mains controversial because it is not es- sons with stroke, and they might be effective in reducing unfavorable outcomes fol- 2-6 lowing ischemic stroke. tablished as safe or effective. A recent open trial demonstrated a modest effect Objective.—To test whether an intravenously administered low molecular from subcutaneously administered hep- weight heparinoid, ORG 10172 (danaparoid sodium), increases the likelihood of a arin in preventing recurrent stroke favorable outcome at 3 months after acute ischemic stroke. within 14 days but no improvement in Design.—Randomized, double-blind, placebo-controlled, multicenter trial. outcomes.7 Thus, whether an intrave- Setting and Participants.—Between December 22, 1990, and December 6, nously administered anticoagulant that 1997, 1281 persons with acute stroke were enrolled at 36 centers across the United would act more rapidly would be effec- States. tiveremainsunanswered.Thesearchfor Intervention.—A 7-day course of ORG 10172 or placebo was given initially as alternative medications that possess the a bolus within 24 hours of stroke, followed by continuous infusion in addition to the antithrombotic characteristics of hepa- best medical care.
    [Show full text]
  • Guidelines for Administration of Anticoagulation for Patients Receiving Haemodialysis Lead Clinician
    Guidelines for administration of Anticoagulation for patients receiving haemodialysis Lead Clinician: Dr. Diwaker Implementation date: January 2014 Last updated: April 2017 Last review date: May 2017 Planned review date: May 2019 Department: Renal Services SaTH Directorate: Medicine Hospital Site: SaTH Keywords: Tinzaparin, Heparin, anti-coagulant, HIT Comments: 1.0 INTRODUCTION The anticoagulant regime should be tailored to the needs of the individual patient, this includes the appropriate anticoagulant drug for the patients clinical condition. When blood comes into contact with the extra corporeal circuit, platelet adherence and activation of the intrinsic clotting cascade occurs, leading to thrombosis. Clots in the dialyser reduce the effective surface area of the dialyser and in extreme situations clots in the circuit may prevent treatment from continuing and result in loss of blood in the circuit. The aim is to anticoagulate the circuit without putting the patient at risk of bleeding. Fractionated heparin (Tinzaparin) is the recommended choice for stable patients on haemodialysis. Heparin is widely used for anticoagulation as the dose can be adjusted. It’s half-life is dramatically less than Tinzaparin. (30mins-2 hours rather than 4-5 hours) Indications for use of heparin would be the unwell CHD, AKI, uraemic patient. Heparin is the anti-coagulant of choice for those patients on Warfarin. We audit the loss of Haemodialysis circuits (ie when the dialysis lines are clotted and blood is lost to the patient). This audit trail shows that the majority of “Lost Circuits” occur when the patient is being dialysed “Heparin Free” or when the ACT guidelines have been misinterpreted.
    [Show full text]
  • Pharmacoepidemiological.Study.Protocol.. ER1379468. A.Retrospective.Cohort.Study.To.Investigate.The.Initiation. And.Persistence.Of.Dual.Antiplatelet.Treatment.After
    Pharmacoepidemiological.study.protocol.ER1379468. % . % % % % % Pharmacoepidemiological.study.protocol.. ER1379468. A.retrospective.cohort.study.to.investigate.the.initiation. and.persistence.of.dual.antiplatelet.treatment.after.. acute.coronary.syndrome.in.a.Finnish.setting.–.THALIA. % Author:(( ( ( Tuire%Prami( Protocol(number:(( %% ER1359468,%ME5CV51306( Sponsor:(( ( ( AstraZeneca%Nordic%Baltic% Protocol(version:(( ( 2.0( Protocol(date:(( ( ( 03%Jul%2014% ( . EPID%Research%Oy%. CONFIDENTIAL. % Pharmacoepidemiological.study.protocol.ER1379468... Version.2.0. 03.Jul.2014. Study Information Title% A% retrospective% cohort% study% to% investigate% the% initiation% and% persistence% of% dual% antiplatelet%treatment%after%acute%coronary%syndrome%in%a%Finnish%setting%–%THALIA% Protocol%version% ER1359468% identifier% ME5CV51306% EU%PAS%register% ENCEPP/SDPP/6161% number% Active%substance% ticagrelor%(ATC%B01AC24),%clopidogrel%(B01AC04),%prasugrel%(B01AC22)% Medicinal%product% Brilique,% Plavix,% Clopidogrel% accord,% Clopidogrel% actavis,% Clopidogrel% krka,% Clopidogrel% mylan,%Clopidogrel%orion,%Clopidogrel%teva%pharma,%Cloriocard,%Efient% Product%reference% N/A% Procedure%number% N/A% Marketing% AstraZeneca%Nordic%Baltic:%Brilique%(ticagrelor)% authorization% holder% financing%the%study% Joint%PASS% No% Research%question% To%describe%initiation%and%persistence%of%dual%antiplatelet%treatment%in%invasively%or%non5 and%objectives% invasively%treated%patients%hospitalized%for%acute%coronary%syndrome%% Country%of%study% Finland% Author% Tuire%Prami%
    [Show full text]
  • Best Evidence for Antithrombotic Agent Reversal in Bleeding
    3/16/2021 1 JAMES H. PAXTON, MD • DIRECTOR OF CLINICAL RESEARCH • DETROIT RECEIVING HOSPITAL (DRH), DEPARTMENT OF EMERGENCY MEDICINE, WAYNE STATE UNIVERSITY • ATTENDING PHYSICIAN • SINAI-GRACE HOSPITAL (SGH) • DETROIT RECEIVING HOSPITAL (DRH) 2 1 3/16/2021 DISCLOSURES • FUNDED RESEARCH SPONSORED BY: TELEFLEX INC, 410 MEDICAL, HOSPI CORP. 3 OBJECTIVES •AT THE CONCLUSION OF THIS LECTURE, THE LEARNER WILL: • RECOGNIZE COMMON ANTITHROMBOTIC MEDICATIONS ASSOCIATED WITH BLEEDING EMERGENCIES • BE ABLE TO EXPLAIN THE MECHANISMS OF ACTION FOR COMMON ANTITHROMBOTIC MEDICATIONS • UNDERSTAND THE EVIDENCE FOR RAPID REVERSAL OF ANTITHROMBOTIC MEDICATIONS, INCLUDING CONTROVERSIES AND BEST PRACTICES HAVE FEWER NIGHTMARES ABOUT SCENES LIKE THE ONE ON THE NEXT SLIDE? 4 2 3/16/2021 BLEEDING IS BAD 5 WHEN TO REVERSE? • WHEN RISK OF BLEEDING OUTWEIGHS RISK OF REVERSAL: • INTRACRANIAL HEMORRHAGE (ICH) • OTHER CNS HEMATOMA (E.G., INTRAOCULAR, SPINAL) • EXSANGUINATING GASTROINTESTINAL (GI) BLEED • UNCONTROLLED RETROPERITONEAL BLEED • HEMORRHAGE INTO EXTREMITY WITH COMPARTMENT SYNDROME • CONSIDER IN POSTERIOR EPISTAXIS, HEMOTHORAX, PERICARDIAL TAMPONADE 6 3 3/16/2021 ANTITHROMBOTIC AGENTS •ANTI-PLATELET DRUGS •ANTI-COAGULANTS •FIBRINOLYTICS 7 THROMBOGENESIS • Primary component in arterial thrombosis (“white clot”) • Target for antiplatelet drugs • Primary component in venous thrombosis (“red clot”) • Aggregated platelets + • Target for anticoagulants fibrin mesh • Target for fibrinolytics 8 4 3/16/2021 PLATELET AGGREGATION Antiplatelet Drugs Mechanism Aspirin*
    [Show full text]
  • Intermittent Calf Compression: a Randomized Trial in Elective Hip
    0276 0277 10:00 h 10:15 h PREVENTION OF DEEP VEIN THROMBOSIS (DVT) IN ABDOMINAL SUR­ INTERMITTENT CALF COMPRESSION: A RANDOMIZED TRIAL IN GERY. A PROSPECTIVE COMPARISON BETWEEN SODIUM PENTOSAN ELECTIVE HIP REPLACEMENT. A. Gall us and T. Darby, Departments of Haematology and Surgery, Flinders Medical POLYSULPHATE AND DEXTRAN 70. D. Bergqvist and H. Ljungner. Centre, Adelaide, South Australia. Department of Surgery, University of Lund, Malmö General We have evaluated venous thrombosis prevention with Hospital, Malmö, Sweden. intermittent calf compression in 78 patients aged over 50 years having elective hip replacement. 38 patients were randomly allotted to intermittent calf compression with a A prospective comparison has been made between PZ 68, "BOC-Roberts Venous Flow Stimulator", begun at the start of sodium pentosan polysulphate, and dextran 70 as prophylac­ surgery and continued for 7 days, while 40 patients had no tic agents against DVT after abdominal surgery. 109 prophylaxis. Age, weight, length of surgery, and other risk patients above 50 years of age were randomly allocated to factors were similar in the two groups. All patients had one of the two groups. The analysis after exclusions is ascending venography of the operated leg on the seventh day, based on 86 patients. PZ 68 was injected 75 mg s.c. twice or bilateral venography if routine 125I fibrinogen leg­ daily for one week and dextran 70 was infused 500 ml per- scanning and impedance plethysmography suggested thrombosis operatively, 500 ml immediately postoperatively and 500 on the unoperated side. ml on the first postoperative day. Diagnosis of DVT was made with the 125-I-fibrinogen test with phlébographie Venography showed thrombosis in 12/38 patients treated verification.
    [Show full text]
  • List Item Refludan : EPAR
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures which have been finalised before 1 August 2003. For scientific information on procedures after this date please refer to module 8B. I Introduction Refludan contains Lepirudin ([Leu1-Thr2]-63-desulfohirudin) as the active substance. Lepirudin is a hirudin analogue produced in yeast cells transfected with an expression vector containing the hirudin gene. Refludan is presented as a powder to be reconstituted with water for injection or with isotonic saline for intravenous injection or infusion. It is supplied in one strength with a standardised content of 50 mg lepirudin per vial. The specific activity of lepirudin is approximately 16,000 (Antithrombin Units) ATU per mg, where one ATU is the amount of hirudin that neutralises one unit of the WHO preparation of thrombin (89/588). Lepirudin is a specific direct inhibitor of free and clot-bound thrombin and the proposed therapeutic indication is anticoagulation in adult patients with heparin-associated thrombocytopenia (HAT) type II and thromboembolic disease mandating parenteral antithrombotic therapy. HAT type II is a complication of heparin therapy, with a probable incidence of the order of 1% of heparin-treated patients. The disorder is characterised by, sometimes profouauthorisednd, thrombocytopenia and a high propensity for venous and arterial thromboembolic complications occurring during continued heparin treatment. Mortality and amputation rates of 20-30% and 10-20%, respectively, are cited in the more recent literature reviews. The chief underlying pathogenic mechanism seems to be a formation of antibodies directed mainly against a complex of heparin and Platelet Factor 4.
    [Show full text]
  • Treatment of Acute Ischemic Stroke
    The New England Journal of Medicine Drug Therapy The molecular events initiated by acute focal ische- mia can be summarized as a time-dependent cascade, characterized by decreased energy production; over- A LASTAIR J.J. WOOD, M.D., Editor stimulation of neuronal glutamate receptors (excito- toxicity); excessive intraneuronal accumulation of sodium, chloride, and calcium ions; mitochondrial in- TREATMENT OF ACUTE ISCHEMIC jury; and eventual cell death (Fig. 1).7, 1 4 -1 6 The funda- STROKE mental goals of intervention are to restore normal cer- ebral blood flow as soon as possible and to protect THOMAS BROTT, M.D., AND JULIEN BOGOUSSLAVSKY, M.D. neurons by interrupting or slowing the ischemic cas- cade.7, 1 4 , 1 5 Studies using magnetic resonance imaging (MRI) and positron-emission tomography suggest that critical ischemia rapidly produces a core of in- SCHEMIC stroke exacts a heavy toll in death and farcted brain tissue surrounded by hypoxic but po- disability worldwide. In the United States, where tentially salvageable tissue.8,17,18 Iit is the third leading cause of death and the lead- ing cause of serious long-term disability, approxi- EARLY EVALUATION AND SUPPORTIVE mately 750,000 strokes occur annually, with an an- TREATMENT nual mortality rate exceeding 150,000.1-4 Only about one third of patients who are having a In June 1996, the Food and Drug Administration stroke are aware of its symptoms, and most bystand- (FDA) approved tissue plasminogen activator (t-PA) ers are not knowledgeable about the signs of stroke. as a safe and effective treatment for stroke if it is giv- When symptoms or signs are recognized, emergency en within three hours after the onset of symptoms of medical services should be notified.19,20 Assessment stroke.5 Subsequently, results of large clinical trials should begin with evaluation of the patient’s airway, testing the efficacy of antiplatelet, antithrombotic, breathing, and circulation — the “ABCs” of resusci- and neuroprotective treatments appeared.
    [Show full text]